Rialto Wealth Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$221 Buy
9
+2
+29% +$56 ﹤0.01% 1877
2026
Q2
$241 Buy
7
+6
+600% +$181 ﹤0.01% 1835
2026
Q1
$24 Sell
1
-4
-80% -$111 ﹤0.01% 1717
2025
Q4
$139 Buy
5
+4
+400% +$102 ﹤0.01% 1586
2025
Q3
$25 Hold
1
– – ﹤0.01% 1692
2025
Q2
$18 Buy
+1
New +$17 ﹤0.01% 1690

Other funds holding BEAM

Rialto Wealth Management's BEAM Position: Q3 2026 in Review

Rialto Wealth Management increased its Beam Therapeutics (BEAM) stake by 29% in Q3 2026, buying an estimated $56 and bringing the position to 9 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Rialto Wealth Management first reported a position in BEAM in Q2 2025 and has held it in 6 quarters since. The position peaked at $241 in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Rialto Wealth Management held 9 shares of Beam Therapeutics worth $221 as of Q3 2026.
  • Rialto Wealth Management bought 2 Beam Therapeutics shares in Q3 2026, an estimated $56.
  • Beam Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q3 2026, its #1877 holding.
  • Rialto Wealth Management first reported a position in Beam Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Rialto Wealth Management's Beam Therapeutics position peaked at $241 in Q2 2026.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Rialto Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.